Arrowhead Pharmaceuticals Financial Statements
NASDAQ: ARWRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arrowhead Pharmaceuticals revenue and earnings
In fiscal 2025, Arrowhead Pharmaceuticals generated $829.4 million in revenue, up 23258.2% from fiscal 2024. Arrowhead Pharmaceuticals reported a net loss of $1.6 million, compared with a loss of $599.5 million a year earlier. Operating margin was 11.9%.
Diluted earnings per share came in at -$0.01. Over the last 5 fiscal years, ARWR's revenue has grown at a 56.6% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Arrowhead Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-09-30 | FY 20242024-09-30 | FY 20232023-09-30 | FY 20222022-09-30 | FY 20212021-09-30 | FY 20202020-09-30 | FY 20192019-09-30 | FY 20182018-09-30 | FY 20172017-09-30 | FY 20162016-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 829.45M | 3.55M | 240.74M | 243.23M | 138.29M | 87.99M | 168.80M | 16.14M | 31.41M | 158.33K |
| Revenue growth (YoY) | +23258.15% | -98.52% | -1.03% | +75.89% | +57.16% | -47.87% | +945.67% | -48.60% | +19736.49% | -58.55% |
| Operating Expenses | 731.10M | 604.63M | 445.74M | 421.74M | 287.32M | 181.15M | 107.61M | 72.08M | 68.40M | 81.90M |
| Research & Development | 607.16M | 505.87M | 353.19M | 297.31M | 206.34M | 128.88M | 81.05M | 52.97M | 50.90M | 62.12M |
| Operating Income | 98.35M | -601.08M | -205.00M | -178.51M | -149.04M | -93.16M | 61.19M | -55.94M | -37.00M | -81.74M |
| Interest Expense | 89.36M | 32.35M | 18.33M | 0 | 0 | — | — | — | — | — |
| Other Income (Expense) | -46.81M | -11.38M | -1.49M | 5.80M | 8.19M | 8.61M | 6.96M | 1.49M | 2.62M | 22.12K |
| Pretax Income | 51.53M | -612.46M | -206.49M | -172.71M | -140.85M | -84.55M | 68.15M | -54.45M | -34.38M | -81.72M |
| Income Tax | 21.42M | -2.77M | 2.78M | 3.79M | 2.00K | 2.00K | 174.00K | 2.40K | 2.40K | 2.40K |
| Net Income | -1.63M | -599.49M | -205.28M | -176.06M | -140.85M | -84.55M | 67.97M | -54.45M | -34.38M | -81.72M |
| Net Income growth (YoY) | — | — | — | — | — | -224.39% | — | — | — | — |
| EPS (Basic) | -0.01 | -5.00 | -1.92 | -1.67 | -1.36 | -0.84 | 0.72 | -0.65 | -0.47 | -1.34 |
| EPS (Diluted) | -0.01 | -5.00 | -1.92 | -1.67 | -1.36 | -0.84 | 0.69 | -0.65 | -0.47 | -1.34 |
| Shares Outstanding (Basic) | 133.76M | 119.78M | 106.75M | 105.43M | 103.75M | 100.72M | 93.86M | 83.64M | 73.90M | 61.05M |
| Shares Outstanding (Diluted) | 133.76M | 119.78M | 106.75M | 105.43M | 103.75M | 100.72M | 98.61M | 83.64M | 73.90M | 61.05M |
| EBITDA | 120.55M | -584.18M | -194.30M | -169.81M | -142.44M | -88.96M | 63.89M | -52.94M | -34.01M | -78.48M |
| Operating Margin | 11.86% | -16927.06% | -85.16% | -73.39% | -107.77% | -105.87% | 36.25% | -346.52% | -117.79% | -51627.09% |
| Net Margin | -20.00% | -16882.37% | -85.27% | -72.39% | -101.85% | -96.09% | 40.27% | -337.32% | -109.46% | -51614.64% |
This table shows 10 annual periods of Arrowhead Pharmaceuticals's income statement, from FY 2025 back to FY 2016, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow ARWR's reporting calendar. What is a income statement?